Home » Stocks » PHGE

BiomX, Inc. (PHGE)

Stock Price: $6.71 USD 0.02 (0.30%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 155.99M
Revenue (ttm) n/a
Net Income (ttm) -41.55M
Shares Out 23.15M
EPS (ttm) -4.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $6.71
Previous Close $6.69
Change ($) 0.02
Change (%) 0.30%
Day's Open 6.58
Day's Range 6.61 - 6.80
Day's Volume 9,051
52-Week Range 4.71 - 10.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today ...

Business Wire - 1 month ago

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today ...

Business Wire - 2 months ago

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today ...

Business Wire - 2 months ago

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today ...

Business Wire - 2 months ago

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today ...

Business Wire - 2 months ago

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, toda...

Business Wire - 2 months ago

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, toda...

Business Wire - 3 months ago

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, toda...

Seeking Alpha - 3 months ago

BiomX is focused on large market opportunities using the unique approach of manipulating the microbiome utilizing phage therapy.

Seeking Alpha - 5 months ago

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today reporte...

Business Wire - 5 months ago

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today an...

The Motley Fool - 5 months ago

Forget traditional IPOs! This blank check vehicle is proving to be an effective tool for biotech companies to raise capital.

Other stocks mentioned: IMVT, TXAC

About PHGE

BiomX, a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targe... [Read more...]

Industry
Biotechnology
Founded
2015
CEO
Jonathan Eitan Solomon MBA
Employees
73
Stock Exchange
NYSEAMERICAN
Ticker Symbol
PHGE
Full Company Profile

Financial Performance

Financial Statements